Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease

JAMA

Volumn 288, Issue 21, 2002, Pages 2724-2731

  Kalayoglu, Murat V ^a   Libby, Peter ^b   Byrne, Gerald I ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MEDLINE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0037021538     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.21.2724     Document Type: Article

References (127)

1. Peeling RW, Brunham RC. Chlamydiae as pathogens: New species and new issues. Emerg Infect Dis. 1996;2:307-319.
2. Ward M. The immunobiology and immunopathology of chlamydial infections. APMIS. 1995;103:769-796.
3. Kalayoglu M, Hahn D, Byrne G. Chlamydia infection and pneumonia. In: Paradise L, Friedman H, eds. Opportunistic Intracellular Bacteria and Immunity. New York, NY: Plenum Publishing; 1998:233-253.
4. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990;161:618-625.
5. Chi EY, Kuo CC, Grayston JT. Unique ultrastructure in the elementary body of Chlamydia sp. strain TWAR. J Bacteriol. 1987;169:3757-3763.
6. Kaukoranta-Tolvanen SS, Laitinen K, Saikku P, Leinonen M. Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathog. 1994; 16:313-319.
7. Gaydos CA, Summersgill JT, Sahney NN, et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996;64:1614-1620.
8. Godzik KL, O'Brien ER, Wang SK, Kuo CC. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol. 1995;33:2411-2414.
9. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis. 1992;15:757-761.
10. Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis. BMJ. 2000; 321:208-213.
11. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet. 1997; 350:430-436.
12. Danesh J, Whincup P, Lewington S, et al. Chlamydia pneumoniae IgA titres and coronary heart disease: Prospective study and meta-analysis. Eur Heart J. 2002;23:371-375.
13. Quinn T. Does Chlamydia pneumoniae cause coronary heart disease? Curr Opin Infect Dis. 1998; 11:301-307.
14. Peeling RW, Wang SP, Grayston JT, et al. Chlamydia pneumoniae serology: Interlaboratory variation in microimmunofluorescence assay results. J Infect Dis. 2000;181 (suppl 3):S426-S429.
15. Rossen RD, Michael LH, Hawkins HK, et al. Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion. Circ Res. 1994;75:546-555.
16. Rebic R, Nastic-Miric D, Pavlovic S, et al. Measuring of cardiolipin antibodies and plasma lipids in different stages of coronary disease. Med Pregl. 1993; 46(suppl 1):20-22.
17. Karvonen M, Tuomilehto J, Pitkaniemi J, et al. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol. 1994;23:1315-1321.
18. Hahn DL, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb. 1992;12:945-947.
19. Boman J, Gaydos CA. Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells. J Infect Dis. 2000;181 (suppl 3): S452-S454.
20. Gieffers J, Fullgraf H, Jahn J, etal. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001; 103:351-356.
21. Mahony JB, Chong S, Coombes BK, et al. Analytical sensitivity, reproducibility of results, and clinical performance of five PCR assays for detecting Chlamydia pneumoniae DNA in peripheral blood mononuclear cells. J Clin Microbiol. 2000;38:2622-2627.
22. Kuo CC, Shor A, Campbell LA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841-849.
23. Kuo CC, Grayston JT, Campbell LA, et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A. 1995;92:6911-6914.
24. Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation. 1995;92:3397-3400.
25. Jackson LA, Campbell LA, Kuo CC, et al. Isolation of Chlamydia pneumoniae from a carotid end-arterectomy specimen. J Infect Dis. 1997;176:292-295.
26. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis. Am J Pathol. 1997;150:1785-1790.
27. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med. 1996;125:979-982.
28. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555-1561.
29. Ong G, Thomas BJ, Mansfield AO, et al. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol. 1996;49:102-106.
30. Weiss SM, Roblin PM, Gaydos CA, et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis. 1996;173:957-962.
31. Juvonen J, Juvonen T, Laurila A, et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg. 1997;25:499-505.
32. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation. 1997;96:2144-2148.
33. Maass M, Bartels C, Kruger S, et al. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. Atherosclerosis. 1998;140(suppl 1):25-30.
34. Paterson DL, Hall J, Rasmussen SJ, Timms P. Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. Pathology. 1998; 30:169-172.
35. Taylor-Robinson D. Ong G, Thomas BJ, et al. Chlamydia pneumoniae in vascular tissues from heart-transplant donors. Lancet. 1998;351:1255.
36. Ouchi K, Fujii B, Kanamoto Y, et al. Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases. J Med Microbiol. 1998;47:907-913.
37. Wong Y, Thomas M, Tsang V, et al. The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery. J Am Coll Cardiol. 1999;33:152-156.
38. Thomas M, Wong Y, Thomas D, et al. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation. 1999; 99:2733-2736.
39. Bartels C, Maass M, Bein G, et al. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenousvein coronary artery bypass grafts. Circulation. 1999;99:879-882.
40. Jantos CA, Nesseler A, Waas W, et al. Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease. Clin Infect Dis. 1999;28:988-992
41. Gibbs RG, Sian M, Mitchell AW, et al. Chlamydia pneumoniae does not influence atherosclerotic plaque behavior in patients with established carotid artery stenosis. Stroke. 2000;31:2930-2935.
42. Chierichetti F, Arbustini E, Arici V, et al. Identification of Chlamydia pneumoniae DNA in carotid plaques. Angiology. 2000;51:827-830.
43. Farsak B, Yildirir A, Akyon Y, et al. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol. 2000;38:4408-4411.
44. Qavi HB, Melnick JL, Adam E, Debakey ME. Frequency of coexistence of cytomegalovirus and Chlamydia pneumoniae in atherosclerotic plaques. Cent Eur J Public Health. 2000;8:71-73.
45. Ericson K, Saldeen TG, Lindquist O, et al. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. Circulation. 2000;101:2568-2571.
46. Karlsson L, Gnarpe J, Naas J, et al. Detection of viable Chlamydia pneumoniae in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2000;19:630-635.
47. Apfalter P, Loidl M, Nadrchal R, et al. Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens. Eur J Clin Microbiol Infect Dis. 2000;19:305-308.
48. Esposito G, Blasi F, Allegra L, et al. Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction. Ann Vasc Surg 1999; 13:421-425.
49. Meijer A, van Der Vliet JA, Roholl PJ, et al. Chlamydia pneumoniae in abdominal aortic aneurysms: Abundance of membrane components in the absence of heat shock protein 60 and DNA. Arterioscler Thromb Vasc Biol. 1999;19:2680-2686
50. Melissano G, Blasi F, Esposito G, et al. Chlamydia pneumoniae eradication from carotid plaques: Results of an open, randomised treatment study. Eur J Vasc Endovasc Surg. 1999;18:355-359.
51. Shor A, Kuo CC, Patton DL, Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 1992;82: 158-161.
52. LaBiche R, Koziol D, Quinn TC, et al. Presence of Chlamydia pneumoniae in human symptomatic and asymptomatic carotid atherosclerotic plaque. Stroke. 2001;32:855-860.
53. Gutierrez J, Linares-Palomino J, Lopez-Espada C, et al. Chlamydia pneumoniae DNA in the arterial wall of patients with peripheral vascular disease. Infection. 2001;29:196-200.
54. Vink A, Poppen M, Schoneveld AH, et al. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual. Circulation. 2001; 103:1613-1617.
55. Beatty W, Morrison R, Byrne G. Persistent chlamydiae: From cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev. 1994;58:686-699.
56. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998;98:300-307.
57. Kaul R, Uphoff J, Wiedeman J, et al. Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease. Circulation. 2000;102:2341-2346.
58. Maass M, Jahn J, Gieffers J, et al. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis. 2000;181(suppl 3):449-451.
59. Moazed TC, Kuo C, Grayston JT, Campbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis. 1997;175:883-890.
60. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, et al. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog. 1996; 21:215-221.
61. Gaydos CA. Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J Infect Dis. 2000;181(suppl 3):S473-S478.
62. Kalayoglu MV, Perkins BN, Byrne GI. Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells. Microbes Infect. 2001;3:963-969.
63. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J infect Dis. 1998;177:725-729.
64. Kalayoglu MV, Miranpuri GS, Golenbock DT, Byrne GI. Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect. 1999;1:409-418.
65. Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun. 1998;66:5067-5072.
66. Kalayoglu MV, Hoerneman B, LaVerda D, et al. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis. 1999;180:780-790.
67. Kalayoglu MV, Indrawati, Morrison RP,etal. Chlamydial virulence determinants in atherogenesis: The role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis. 2000;181(suppl 3):S483-S489.
68. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation. 1999;99:1560-1566.
69. Mayr M, Kiechl S, Willeit J, et al. Infections, immunity, and atherosclerosis: Associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heatshock protein 60 and carotid or femoral atherosclerosis. Circulation. 2000;102:833-839.
70. Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, et al. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb Pathog. 1996;21:407-411.
71. Liuba P, Karnani P, Pesonen E, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation. 2000;102:1039-1044.
72. Molestina RE, Miller RD, Ramirez JA, Summersgill JT. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect Immun. 1999;67:1323-1330.
73. Summersgill JT, Molestina RE, Miller RD, Ramirez JA. Interactions of Chlamydia pneumoniae with human endothelial cells. J Infect Dis. 2000;181(suppl 3): S479-S482.
74. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappa B and induces tissue factor and PAI-1 expression: A potential link to accelerated arteriosclerosis. Circulation. 1999; 100:1369-1373.
75. Fryer RH, Schwobe EP, Woods ML, Rodgers GM. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med. 1997;45:168-174.
76. Coombes BK, Mahony JB. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cellderived soluble factor(s). Infect Immun. 1999;67: 2909-2915.
77. Miller SA, Selzman CH, Shames BD, et al. Chlamydia pneumoniae activates nuclear factor kappa B and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. J Surg Res. 2000;90:76-81.
78. Netea MG, Selzman CH, Kullberg BJ, et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol. 2000;30:541-549.
79. Geng Y, Shane RB, Berencsi K, et al. Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10. J Immunol. 2000;164:5522-5529.
80. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 2000;101:1760-1763.
81. de Boer OJ, van der Wal AC, Houtkamp MA, et al. Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. Cardiovasc Res. 2000;48:402-408.
82. Halme S, Juvonen T, Laurila A, et al. Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms. Eur J Clin Invest. 1999;29: 546-552.
83. Mosorin M, Surcel HM, Laurila A, et al. Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery. Arterioscler Thromb Vasc Biol. 2000;20:1061-1067.
84. Sakash JB, Byrne GI, Lichtman A, Libby P. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-associated cells: Implications for persistent Chlamydophila pneumoniae infection. Infect Immun. 2002;70:3959-3961.
85. Vehmaan-Kreula P, Puolakkainen M, Sarvas M, et al. Chlamydia pneumoniae proteins induce secretion of the 92-kDa gelatinase by human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 2001;21:E1-E8.
86. Koch R. Die aetiologie der tuberculose. Berl Klin Wochenschr. 1882;19:221-230.
87. Caligiuri G, Rottenberg M, Nicoletti A, et al. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation. 2001;103:2834-2838.
88. Aalto-Setala K, Laitinen K, Erkkila L, et al. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:578-584.
89. Campbell LA, Blessing E, Rosenfeld M, et al. Mouse models of C. pneumoniae infection and atherosclerosis. J Infect Dis. 2000;181(suppl 3):S508-S513.
90. Hu H, Pierce GN, Zhong G. The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest. 1999;103:747-753.
91. Muhlestein JB. Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. J Infect Dis. 2000;181(suppl 3):505-507.
92. Fong IW, Chiu B, Viira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35:48-52.
93. Laitinen K, Laurila A, Pyhala L, et al. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun. 1997;65:4832-4835.
94. Richardson M, De Reske M, Delaney K, et al. Respiratory infection in lipid-fed rabbits enhances sudanophilia and the expression of VCAM-1. Am J Pathol. 1997;151:1009-1017.
95. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med. 1978; 148:335-340.
96. Burnett MS, Gaydos CA, Madico GE, et al. Atherosclerosis in apoE knockout mice infected with multiple pathogens. J Infect Dis. 2001;183:226-231.
97. Fong IW. Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. J Infect Dis. 2000;181 (suppl 3):S514-S518.
98. Mach F, Sukhova GK, Michetti M, et al. Influence of Helicobacter pylori infection during athero-genesis in vivo in mice. Circ Res. 2002;90:E1-E4.
99. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633-636.
100. Rothstein NM, Quinn TC, Madico G, et al. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J Infect Dis. 2001; 183:232-238.
101. Fong IW, Chiu B, Viira E, et al. Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. Antimicrob Agents Chemother. 2002;46:2321-2326.
102. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
103. Gurfinkel E, Bozovich G, Daroca A, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet. 1997; 350:404-407.
104. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study. Circulation. 2000;102:1755-1760.
105. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation. 1999;99:1540-1547.
106. Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: A randomized, double-blind, placebo-controlled trial. Circulation. 2002;105:2646-2652.
107. Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation. 2002;106:1219-1223.
108. Grayston J. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. In: Stephens R, Byrne G, Christiansen G, et al, eds. Proceedings of the 9th International Symposium on Human Chlamydial Infection. San Francisco, Calif: International Chlamydia Symposium; 1998: 187-190.
109. Anderson JL, Muhlestein JB. The ACADEMIC study in perspective (Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia). J Infect Dis. 2000;181(suppl 3):S569- S571.
110. Cercek B, Azithromycin in Acute Coronary Syndrome Investigators. The effect of short term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndrome. J Am Coll Cardiol. 2002;39(suppl A):405-413.
111. Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: The WIZARD (Weekly Intervention with Zithromax [azithromycin] for Atherosclerosis and its Related Disorders) trial. J Infect Dis. 2000;181(suppl 3):S572-S578.
112. Jackson LA. Description and status of the Azithromycin and Coronary Events Study (ACES). J Infect Dis. 2000;181(suppl 3):S579-S581.
113. Frothingham C. The relationship between acute infectious diseases and arterial lesions. Arch Intern Med. 1911;8:153-162.
114. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336:973-979.
115. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ. 2000; 321:199-204.
116. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115-126.
117. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
118. Apfalter P, Blasi F, Boman J, et al. Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in end-arterectomy specimens. J Clin Microbiol. 2001;39: 519-524.
119. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis. 2001;33:492-503.
120. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000; 181(suppl 3):S462-S472.
121. Cook PJ, Lip GY, Davies P, et al. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension. 1998;31:589-594.
122. Mahdi OS, Horne BD, Mullen K, etal. Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease. Circulation. 2002;106:1659-1663.
123. Rugonfalvi-Kiss S, Endresz V, Madsen HO, et al. Association of Chlamydia pneumoniae with coronary artery disease and its progression is dependent on the modifying effect of mannose-binding lectin. Circulation. 2002;106:1071-1076
124. Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 2000; 85:140-146.
125. Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001;103:45-51.
126. Wright SD, Burton C, Hernandez M, et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med. 2000;191:1437-1442.
127. Schwartz B, Bell DM, Hughes JM. Preventing the emergence of antimicrobial resistance: A call for action by clinicians, public health officials, and patients. JAMA. 1997;278:944-945.